Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1618 1641
This examiner grants 55% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19176436 | PHARMACEUTICAL COMPOSITIONS OF RIBOCICLIB | Non-Final OA | Novartis AG |
| 17754059 | RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC | Final Rejection | NOVARTIS AG |
| 18056599 | Formulations for the Suprachoroidal Space of an Eye and Methods | Final Rejection | Georgia Tech Research Corporation |
| 17700987 | FLUORESCENT PROBES FOR MONOACYLGLYCEROL LIPASE (MAGL) | Non-Final OA | Hoffmann-La Roche Inc. |
| 17737229 | INTRANASAL ADMINISTRATION OF GLUTAMATE CARBOXYPEPTIDASE (GCP-II) INHIBITORS | Final Rejection | The Johns Hopkins University |
| 18103932 | IODINATED COMPOUNDS AND HYDROGELS FORMED FROM SAME | Non-Final OA | Boston Scientific Scimed, Inc. |
| 17475794 | NON-FIBROUS FILM AND CELL SHEET | Non-Final OA | Industrial Technology Research Institute |
| 18223714 | LOADING OF HUMAN CAR T-CELLS WITH SUPERPARAMAGNETIC IRON-BASED PARTICLES FOR MAGNETIC TARGETING | Non-Final OA | FRIEDRICH-ALEXANDER-UNIVERSITÄT ERLANGEN-NÜRNBERG |
| 18010759 | CHEMOKINE-SELECTIVE CXCR4 ECTODOMAIN-DERIVED (POLY)PEPTIDE | Non-Final OA | Technische Universität München |
| 18252969 | Liquid Composition Comprising Cereal Beta-Glucan or a Cereal Extract Comprising Beta-Glucan | Non-Final OA | Symrise AG |
| 17636107 | IN VIVO IMMUNOIMAGING OF INTERLEUKIN-12 | Non-Final OA | Wayne State University |
| 18116737 | POLYMERS, SYSTEMS, AND METHODS FOR USING AND MONITORING POLYMERS FOR USE IN MEDICAL POLYMERS, IMPLANTS, AND PROCEDURES | Final Rejection | CANARY MEDICAL SWITZERLAND AG |
| 18042806 | MRI CONTRAST MEDIUM INCLUDING CARBON-13-CONTAINING GRAPHENE QUANTUM DOT AND PREPARATION METHOD THEREFOR | Non-Final OA | SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION |
| 18612370 | CONTROLLED RELEASE FORMULATIONS FOR THE TREATMENT OF MALARIA | Non-Final OA | KARICI DIAGNOSTICS INC. |
| 18612007 | Carrier Systems For Cannabinoids | Non-Final OA | Fertin Pharma A/S |
| 17910199 | COMPOSITIONS AND METHODS FOR NALOXONE DELIVERY | Non-Final OA | Purdue Pharma L.P. |
| 17551289 | VISCOSIFIED FLUIDS FOR MEDICAMENT DELIVERY | Non-Final OA | Palo Alto Research Center Incorporated |
| 18573077 | Liquid Filled Capsule with Two Phase Liquid Fill | Non-Final OA | Lonza Greenwood LLC |
| 17769424 | CONTROLLED RELEASE FORMULATIONS OF HIGHLY LIPOPHILIC PHYSIOLOGICALLY ACTIVE SUBSTANCES | Final Rejection | ADD Advanced Drug Delivery Technologies Ltd. |
| 18462235 | METHODS AND COMPOSITIONS FOR DELIVERING MYCOPHENOLIC ACID ACTIVE AGENTS TO NON-HUMAN MAMMALS | Non-Final OA | Okava Pharmaceuticals, Inc. |
| 18254904 | SKIN-CLEANSING PRODUCT AND METHOD FOR OBTAINING SAID PRODUCT | Non-Final OA | ECZACIBASI TUKETIM URUNLERI SANAYI VE TICARET ANONIM SIRKETI |
| 17611929 | RADIOTHERAPEUTIC MICROSPHERES | Final Rejection | PLUS THERAPEUTICS, INC. |
| 18252012 | ENHANCED UPTAKE TRANSMUCOSAL DRUG DELIVERY COMPOSITIONS AND METHODS OF USE | Non-Final OA | Padagis Israel Pharmaceuticals Ltd. |
| 18009699 | IMAGING COMPOUNDS SELECTIVE FOR NaV1.7 | Non-Final OA | MEMORIAL SLOAN KETTERING CANCER CENTER |
| 18040024 | GALLIUM-LABELED GASTRIN ANALOGUE AND USE IN A METHOD OF IMAGING CCKB-RECEPTOR-POSITIVE TUMORS OR CANCERS | Non-Final OA | Paul Scherrer Institut |
| 18011664 | Methods For Reducing Catecholamine-Formaldehyde Adducts | Non-Final OA | Nevakar Injectables Inc. |
| 16143678 | PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION | Non-Final OA | AQUESTIVE THERAPEUTICS, INC. |
| 17906914 | METHOD OF DIFFERENTIATING OF A CHRONIC KIDNEY DISEASE OR GLOMERULOPATHY, METHOD OF MONITORING A RESPONSE TO TREATMENT OF A CHRONIC KIDNEY DISEASE OR GLOMERULOP ATHY IN A SUBJECT AND A METHOD OF TREATMENT OF A CHRONIC KIDNEY DISEASE OR GLOMERULOPATHY | Non-Final OA | INSTYTUT BIOCHEMII I BIOFIZYKI PAN |
| 17761918 | NICOTINE POUCH | Final Rejection | Enorama Pharma AB |
| 17760854 | METHODS OF DETECTING NEUROLOGICAL DISORDERS VIA BINDING TO PHOSPHORYLATED TAU PROTEIN | Final Rejection | Amydis, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy